SpecialtiesQuestion

When a patient with ICI-induced inflammatory arthritis requires biologic DMARD therapy, how do you balance need to treat with concern for faster cancer progression?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

For ICI arthritis, how soon do you start DMARDs?

For a patient with ICI toxicity who is resistant to the use of high-dose steroids, are there scenarios where you would consider the use of first-line conventional synthetic DMARD in place of steroids?

Is there any role for prophylactic DMARD therapy to prevent immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors?

How do you decide on the next therapy for post-ICI triple M syndrome (myositis/myocarditis/myasthenia) after steroids, PLEX, and IVIG?

Do you manage a patient presenting with ICI-induced PMR-like syndrome using the same glucocorticoid dosing and tapering schedule you would apply to primary PMR, or do you treat it as a distinct entity requiring a lower steroid dose given evidence suggesting it tends to be milder?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.